Author: Houston Stringer

HOUSTON, TX – A Houston-based clinical-stage biotechnology company (NASDAQ: COYA) announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COYA 302, a biologic therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS). Coya Therapeutics Logo The FDA’s acceptance enables the company to begin a Phase 2 multicenter, double-blind, placebo-controlled clinical study evaluating the efficacy and safety of COYA 302 in ALS patients. The approval also triggers a $4.2 million milestone payment from its partner, Dr. Reddy’s Laboratories Ltd. According to the company, COYA 302 is a proprietary combination therapy designed to enhance the anti-inflammatory function of regulatory T cells and suppress inflammat...

ARANSAS COUNTY, TX – The Rockport Volunteer Fire Department, alongside multiple mutual aid partners, responded to the Aransas 4010 Fire near Cape Valero on August 22, 2025. The fire burned approximately 54 acres of wetlands and heavy brush before being fully contained. No homes or structures were lost or damaged, though firefighters reported several were threatened and defended successfully. Agencies assisting included Rockport VFD, Fulton VFD, Lamar VFD, Aransas Pass VFD, Ingleside VFD, Bayside VFD, and Refugio VFD. Rockport VFD extended thanks to its neighboring departments for their teamwork and dedication. A special acknowledgment was given to Mac’s Pit Barbecue & Catering for providing food and supplies to support fire crews during operations. The Rockport Voluntee...